
Opinion|Videos|May 8, 2024
Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma
Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
MONALEESA Data Reveal Robust Long-Term Disease Control With Ribociclib
2
Advancing Treatment After CDK4/6 Inhibitor Progression in HR+/HER2– Breast Cancer
3
Pharmacists, Don’t Fear AI: ASHP Framework Shows How to Embrace AI
4
A Supplemental Blood Test to Bridge Gaps in Breast Cancer Screening Access
5





















































































































































































































